Treatment frontiers
Treatment frontiers Nature 467, 622 (2010). doi:10.1038/nature09476 Author: Kerri Smith Nature466 (suppl.), S15–S18 (10.1038/466S15a26 August 2010)This Outlook article stated that Addex Pharmaceuticals has mGluR5 modulators in phase II trials for anxiety and depression. The company says that its only disclosed mGluR5 inhibitor in development, ADX48621, will soon
